Volume | 178,336 |
|
|||||
News | - | ||||||
Day High | 1.08 | Low High |
|||||
Day Low | 1.02 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Oncolytics Biotech Inc | ONCY | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.08 | 1.02 | 1.08 | 1.04 | 1.08 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
458 | 178,336 | $ 1.04 | $ 185,371 | - | 0.883 - 3.3942 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:39:45 | formt | 250 | $ 1.08 | USD |
Oncolytics Biotech Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
77.04M | 73.37M | - | 0 | -27.75M | -0.38 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Oncolytics Biotech News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ONCY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.08 | 1.16 | 1.01 | 1.11 | 292,429 | 0.00 | 0.00% |
1 Month | 1.01 | 1.29 | 1.00 | 1.11 | 265,777 | 0.07 | 6.93% |
3 Months | 1.23 | 1.3103 | 0.883 | 1.06 | 393,394 | -0.15 | -12.20% |
6 Months | 1.86 | 1.8759 | 0.883 | 1.26 | 410,662 | -0.78 | -41.94% |
1 Year | 1.15 | 3.3942 | 0.883 | 1.99 | 576,799 | -0.07 | -6.09% |
3 Years | 2.92 | 3.3942 | 0.8021 | 1.99 | 355,487 | -1.84 | -63.01% |
5 Years | 1.95 | 6.02 | 0.351 | 2.42 | 590,065 | -0.87 | -44.62% |
Oncolytics Biotech Description
Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The company's product pipeline includes Bavencio, Keytruda, Retifanlimab, and Tecentriq. |